AstraZeneca plc (AZN) Given Hold Rating at Liberum Capital
Liberum Capital restated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Tuesday. They currently have a GBX 5,200 ($67.88) price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also weighed in on the company. Bryan, Garnier & Co restated a buy rating on shares of AstraZeneca plc in a research note on Thursday, July 28th. Morgan Stanley restated an overweight rating and issued a GBX 5,000 ($65.27) target price on shares of AstraZeneca plc in a research note on Monday, July 11th. Credit Suisse Group AG restated an underperform rating and issued a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc in a research note on Monday, June 27th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on AstraZeneca plc and gave the stock a sell rating in a research note on Tuesday. Finally, Jefferies Group upped their target price on AstraZeneca plc from GBX 4,100 ($53.52) to GBX 4,450 ($58.09) and gave the stock a hold rating in a research note on Thursday, June 30th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc has a consensus rating of Hold and an average price target of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) traded down 0.04% during midday trading on Tuesday, reaching GBX 5023.00. The company’s stock had a trading volume of 1,040,959 shares. The company’s market capitalization is GBX 63.54 billion. The company’s 50-day moving average price is GBX 5,009.44 and its 200 day moving average price is GBX 4,418.92. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00.
The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.